Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Santen Inc.
This is a 90-day randomized, observer-masked, active-controlled, parallel-group, multi-center, study assessing the safety and efficacy of five concentrations of DE-117 ophthalmic solution when compared to latanoprost (0.005% latanoprost) in subjects with primary open-angle glaucoma or ocular hypertension.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Current diagnosis of primary open-angle glaucoma or ocular hypertension in both eyes
Qualifying intraocular pressure in at least one eye at Baseline
Qualifying corrected ETDRS visual acuity in each eye
Qualifying central cornea thickness in each eye
You may not be if
Closed/barely open anterior chamber angle or a history of acute angle closure in either eye
Diagnosis of primary open-angle glaucoma or ocular hypertension due to etiology known to be non-responsive to conventional drug therapy
Evidence of advanced glaucoma, visual field defect or progressive visual field loss that that do not meet the study criteria
History of ocular surgery specifically intended to lower IOP
History of any ocular or systemic abnormality or condition that may put the subject at significant risk, may confound study results, or may interfere significantly with the subject's participation in the study
Intended or current use of any ocular medications other than study medications during the study
Use of contact lenses within one week prior to Baseline (Day 1) until end of treatment
Known allergy or sensitivity to any components of the study medications
Use of steroids (systemic) within 30 days prior to Visit 1 (Screening)
Anticipate the need to initiate or modify an existing chronic therapy that could substantially affect IOP or the study outcomes during the study period
Females who are pregnant, nursing or planning a pregnancy
Clareo Health | Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
